Stock Events

Stock Events

Mannkind 

$4.07
133
+$0.11+2.65% 15:29 Today

Statistics

Day High
4.08
Day Low
3.92
52W High
6.51
52W Low
2.23
Volume
796,906
Avg. Volume
4,513,280
Mkt Cap
1.31B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.06
-0.02
0.01
0.05
Expected EPS
-0.05625
Actual EPS
N/A

Financials

1.68%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
348.97MRevenue
5.86MNet Income

Analyst Ratings

10.00Average Price Target
The highest estimate is 13.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MNKD. It's not an investment recommendation.
NVIDIA
20
NVDA
Amazon
19
AMZN
Realty Income
17
O
Tesla
17
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sanofi
SNY
Mkt Cap107.39B
Sanofi, with its diabetes and insulin products, competes directly with MannKind's inhaled insulin, Afrezza.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a leading company in diabetes care with a wide range of insulin products, competing in the same market as MannKind.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly is a major player in the diabetes care market, offering insulin and other diabetes treatments that compete with MannKind's offerings.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in the diabetes care sector, offering products that compete with MannKind's diabetes treatments.
Merck
MRK
Mkt Cap366B
Merck produces diabetes medications, including oral treatments that serve as alternatives to MannKind's inhaled insulin.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb offers a range of diabetes treatments, competing in the broader diabetes care market against MannKind.
Tandem Diabetes Care
TNDM
Mkt Cap1.49B
Tandem Diabetes Care specializes in insulin delivery systems, offering products that can be seen as alternatives to MannKind's Afrezza.
Insulet
PODD
Mkt Cap10.07B
Insulet Corporation provides innovative insulin management systems, competing in the insulin delivery market alongside MannKind.
Dexcom
DXCM
Mkt Cap34.27B
DexCom, Inc. specializes in glucose monitoring systems, which are essential for diabetes management, indirectly competing with MannKind by offering complementary diabetes care solutions.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories offers glucose monitoring systems and other diabetes care products, competing in the broader market for diabetes management solutions.

About

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Show more...
CEO
Michael E. Castagna
Employees
592
Country
United States
ISIN
US56400P7069
WKN
000A2DMZL

Listings

STU
DE
NNFN.STU
F
DE
NNFN.F
MU
DE
NNFN.MU
XNAS
US
MNKD

0 Comments

Share your thoughts

FAQ

What is Mannkind stock price today?▼
The current price of MNKD is $4.07 USD — it has increased by +2.65% in the past 24 hours. Watch Mannkind stock price performance more closely on the chart.
What is Mannkind stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Mannkind stocks are traded under the ticker MNKD.
Is Mannkind stock price growing?▼
MNKD stock has risen by +2.91% compared to the previous week, the month change is a +2.65% rise, over the last year Mannkind has showed a -23.88% decrease.
What is Mannkind market cap?▼
Today Mannkind has the market capitalization of 1.31B
When is the next Mannkind earnings date?▼
Mannkind is going to release the next earnings report on November 10, 2026.
What were Mannkind earnings last quarter?▼
MNKD earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.01 USD resulting in a -700% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mannkind revenue for the last year?▼
Mannkind revenue for the last year amounts to 348.97M USD.
What is Mannkind net income for the last year?▼
MNKD net income for the last year is 5.86M USD.
How many employees does Mannkind have?▼
As of September 04, 2026, the company has 592 employees.
In which sector is Mannkind located?▼
Mannkind operates in the Health & Wellness sector.
When did Mannkind complete a stock split?▼
The last stock split for Mannkind was on March 03, 2017 with a ratio of 1:5.
Where is Mannkind headquartered?▼
Mannkind is headquartered in DANBURY, United States.